NCT06182657 The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC
| NCT ID | NCT06182657 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jiangxi Provincial Cancer Hospital |
| Condition | Nasopharyngeal Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2024-01-01 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to explore the prognostic value of pathological remission after one cycle of induction chemotherapy in locally advanced nasopharyngeal carcinoma, and the change of immune micro-environment after one cycle induction chemotherapy, including the density of immune cells infiltration and tertiary lymphoid structures.
Eligibility Criteria
Inclusion Criteria: 1. Ability to sign informed consent 2. Age \> 18 years at time of study entry 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (amend based on specific study) 4. Histological confirmation of NPC (regardless if EBER positive or negative) 5. Locally advanced NPC, UICC stage III-IVa 6. Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up. Exclusion Criteria: 1. Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study 2. Distant metastases 3. Prior systemic anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, radiotherapy, biologic therapy, tumour embolization, monoclonal antibodies) of the locally advanced NPC. 4. History of another primary malignancy 5. Female patients who are pregnant 6. Known allergy or hypersensitivity to any drugs 7. Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.
Contact & Investigator
Jingao Li, PhD
PRINCIPAL INVESTIGATOR
Jiangxi Provincial Cancer Hospital
Frequently Asked Questions
Who can join the NCT06182657 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Nasopharyngeal Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06182657 currently recruiting?
Yes, NCT06182657 is actively recruiting participants. Contact the research team at lijingao@hotmail.com for enrollment information.
Where is the NCT06182657 trial being conducted?
This trial is being conducted at Nanchang, China.
Who is sponsoring the NCT06182657 clinical trial?
NCT06182657 is sponsored by Jiangxi Provincial Cancer Hospital. The principal investigator is Jingao Li, PhD at Jiangxi Provincial Cancer Hospital. The trial plans to enroll 300 participants.